For the year ending 2025-12-31, PCRX had -$118,229K decrease in cash & cash equivalents over the period. $136,661K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 7,034 |
| Goodwill impairment | 0 |
| Indefinite-lived intangible asset impairment | 25,866 |
| Investment impairment | 11,000 |
| Loss on lease terminations | 0 |
| Deferred taxes | 6,477 |
| Depreciation of fixed assets and amortization of intangible assets | 91,023 |
| Amortization of debt issuance costs and debt discount | 2,997 |
| Loss (gain) on early extinguishment of debt | -983 |
| Stock-based compensation | 57,502 |
| Changes in contingent consideration | -2,175 |
| Net accretion of discount on available-for-sale investments | 4,927 |
| Other net (gains) losses | -5,520 |
| Accounts receivable, net | 10,742 |
| Inventories, net | 27,567 |
| Prepaid expenses and other assets | 1,212 |
| Accounts payable | -5,598 |
| Accrued expenses and other liabilities | 6,853 |
| Net cash provided by operating activities | 151,994 |
| Acquisition of gq bio therapeutics gmbh (net of cash acquired) | 16,702 |
| Purchases of fixed assets | 15,333 |
| Purchases of available-for-sale investments | 141,041 |
| Sales of available-for-sale investments | 273,807 |
| Purchases of debt and equity investments | 1,250 |
| Net cash provided by (used in) investing activities | 99,481 |
| Proceeds from exercises of stock options | 502 |
| Proceeds from shares issued under employee stock purchase plan | 2,801 |
| Payment of employee withholding taxes on restricted stock unit vests | 5,617 |
| Purchase of treasury stock, inclusive of broker fees | 148,328 |
| Proceeds from revolving credit facility | 101,000 |
| Proceeds from 2029 convertible senior notes | 0 |
| Proceeds from term loan a facility | 0 |
| Repayments of convertible senior notes-Convertible Senior Notes Due2024 | 0 |
| Repayments of convertible senior notes-Convertible Senior Notes Due2025 | 202,487 |
| Repayment of term loan facility-Term Loan BFacility | 0 |
| Repayment of term loan facility-Term Loan AFacility | 105,312 |
| Repayment of revolving credit facility | 10,000 |
| Purchase of capped call transactions | 0 |
| Debt extinguishment costs | 0 |
| Payment of debt issuance and financing costs | 2,186 |
| Net cash (used in) provided by financing activities | -369,627 |
| Effect of exchange rate changes on cash and cash equivalents | -77 |
| Net (decrease) increase in cash and cash equivalents | -118,229 |
| Cash and cash equivalents, beginning of year | 276,774 |
| Cash and cash equivalents, end of year | 158,545 |
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)